Panbela Schedules Conference Call on August 11, 2021, to Report 2021 Second Quarter Financial Results

In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression or peripheral neuropathy, which can be chemotherapy-related adverse events.